The main obstacle to better antimicrobial resistance (AMR) management is not a technological deficit. Advanced diagnostics exist, but healthcare systems struggle to implement them. The key is generating real-world evidence and health economic data to convince policymakers and change clinical practice.

Shifting from clinician-ordered to pathologist-initiated reflex testing for NSCLC biomarkers combines diagnosis and molecular analysis into one workflow. This operational change minimizes delays, increases testing rates, and optimizes the use of small biopsy samples, getting actionable results to oncologists faster.

Urgency is forcing a major shift in hospital procurement. CIOs are no longer willing to wait years for incumbents like Epic to develop AI tools. They are actively partnering with startups to deploy commercially ready solutions now, prioritizing speed and immediate operational impact over vendor loyalty.

The ambitious goal of prescribing no antibiotics without a diagnostic by 2030 cannot be achieved by technology alone. It requires a systemic effort involving national action plans and policy reinforcement, driven by partnerships between public entities, private companies, academics, policymakers, and scientists.

Unlike other resistant bacteria like MRSA which can be cleared from the body, CPE colonizes the gut and has no proven therapy for eradication. Patients can remain carriers for months or years. This critical difference makes rapid screening and transmission prevention the only effective long-term strategy.

To overcome logistical delays, a hybrid lab testing model is effective. It uses local labs for rapid eligibility screening to accelerate patient enrollment, while simultaneously using central labs for standardized, confirmatory validation. This approach balances the need for speed with the requirement for rigorous, reliable data.

Even for common conditions like pneumonia, current diagnostic methods like sputum and blood cultures fail to identify a bacterial cause in 60% of cases. This diagnostic gap leads to clinical guesswork, resulting in dangerous under-treatment. In one study, one in eight patients with a bacterial infection was sent home from the ER without antibiotics.

The field of infectious disease is moving away from empirical treatment toward its own version of precision medicine. Similar to how oncology uses companion diagnostics to guide therapy, new rapid molecular tests are enabling clinicians to identify the specific organism and its resistance profile to prescribe the right antibiotic at the right time.

The most dangerous phase for spreading drug-resistant bacteria like CPE is the asymptomatic 'colonization' stage. During this period, individuals act as silent carriers, spreading the bacteria easily because no contact precautions are in place. Rapid diagnostics are essential to identify these individuals before they trigger an outbreak.